Why the study?
Does an elevated INR (> 1.2) in the absence of anticoagulant therapy predict higher mortality in patients presenting with acute pulmonary embolism?
Does an elevated INR (> 1.2) in the absence of anticoagulant therapy predict higher mortality in patients presenting with acute pulmonary embolism?
In patients with acute pulmonary embolism not on anticoagulants, an elevated INR > 1.2 is a strong independent predictor of 6-month mortality and improves risk stratification beyond the sPESI score.
Answers are grounded in this paper and cite their sources.
May signal higher mortality in untreated PE; leaves open need for prospective validation before clinical use.
The prognostic significance of patients presenting with pulmonary embolism (PE) and elevated International Normalised Ratio (INR) not on anticoagulant therapy has not been described. We investigated whether these patients had higher mortality compared to patients with normal INR. A retrospective study of patients admitted to a tertiary hospital with acute PE from 2000 to 2012 was undertaken, with study outcomes tracked using a state-wide death registry. Patients were excluded if they were taking anticoagulants or had inadequate documentation of their INR and medication status. Of the 1,039 patients identified, 94 (9 %) had an elevated INR (> 1.2) in the absence of anticoagulant use. These patients had higher mortality at six months follow-up (26 % vs 6 %, p< 0.001) compared to controls (INR ≤ 1.2). An INR > 1.2 at diagnosis was an independent predictor of death at six months post-PE (hazard ratio [HR] 2.9, 95 % confidence interval [CI] 1.8-4.7, p< 0.001). The addition of INR to a multivariable model that included the simplified pulmonary embolism severity index (sPESI), chest pain, and serum sodium led to a significant net reclassification improvement estimated at 8.1 %. The final model's C statistic increased significantly by 0.04 (95 % CI 0.01-0.08, p=0.03) to 0.83 compared to sPESI alone (0.79). In summary, patients presenting with acute PE and elevated INR while not on anticoagulant therapy appear to be at high risk of death. Future validation studies in independent cohorts will clarify if this novel finding can be usefully incorporated into clinical decision making in patients with acute PE.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: